All 10 drugmakers agree to negotiate Medicare drug prices despite legal challenges

All manufacturers of the first 10 drugs chosen for Medicare price negotiations have agreed to participate in the talks.
The selected drugs accounted for $3.4 billion in out-of-pocket costs for Medicare enrollees last year.
The negotiations are a result of President Biden's Inflation Reduction Act, with reduced prices taking effect in 2026.
Some drugmakers are suing to try to stop the negotiations but agreed to comply to avoid penalties.
Medicare will continue selecting more drugs each year for price negotiations aimed at lowering costs.